Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.675
+0.065 (1.80%)
At close: Nov 4, 2024, 4:00 PM
3.580
-0.095 (-2.59%)
After-hours: Nov 4, 2024, 4:23 PM EST
Kiora Pharmaceuticals Revenue
Kiora Pharmaceuticals had revenue of $20.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $16.02M.
Revenue (ttm)
$16.02M
Revenue Growth
n/a
P/S Ratio
0.49
Revenue / Employee
$1,335,000
Employees
12
Market Cap
10.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 169.19M |
Dominari Holdings | 9.51M |
PAVmed | 3.83M |
Alterity Therapeutics | 2.68M |
Biora Therapeutics | 860.00K |
BioRestorative Therapies | 174.10K |
KPRX News
- 6 days ago - Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Newsfile Corp
- 5 weeks ago - Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - Newsfile Corp
- 4 months ago - Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Newsfile Corp
- 4 months ago - Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - Newsfile Corp